Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

ESMO open·2025
Same author

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.

Breast cancer research and treatment·2019
Same author

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Related Experiment Video

Updated: Mar 30, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.2K

Carboplatin-Loaded PLGA Microspheres for Intracerebral Implantation: In Vivo Characterization.

W Chen1, J He2, J J Olson2

  • 1a Department of Pharmaceutics, College of Pharmacy, University of Georgia, Athens, Georgia, USA.

Drug Delivery
|November 20, 2015
PubMed
Summary

Injectable microspheres offer a new way to deliver carboplatin directly to brain tumors, bypassing the blood-brain barrier. This local delivery method minimizes side effects and shows promise for treating malignant glioma.

Keywords:
BiodegradableCarboplatinInjectable MicrospheresIntracerebral ImplantationPLGA

More Related Videos

Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma
11:02

Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma

Published on: August 9, 2022

3.7K
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.8K

Related Experiment Videos

Last Updated: Mar 30, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.2K
Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma
11:02

Flexible Organic Electronic Devices for Pulsed Electric Field Therapy of Glioblastoma

Published on: August 9, 2022

3.7K
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.8K

Area of Science:

  • Biomedical Engineering
  • Neuro-oncology
  • Drug Delivery Systems

Background:

  • Malignant glioma is a deadly brain cancer requiring high drug doses.
  • The blood-brain barrier (BBB) limits effective systemic drug delivery.
  • High systemic doses of chemotherapy cause severe side effects.

Purpose of the Study:

  • To evaluate carboplatin-loaded biodegradable microspheres for local brain tumor treatment.
  • To assess the safety and efficacy of intracerebral microsphere delivery.
  • To investigate the in vivo release kinetics and biodegradation of microspheres.

Main Methods:

  • Carboplatin-loaded biodegradable microspheres were prepared.
  • Microspheres were delivered intracerebrally into rats.
  • Systemic and neurologic toxicity were monitored.
  • In vivo drug release and microsphere biodegradation were analyzed.

Main Results:

  • No systemic or neurologic toxicity was observed from implanted microspheres.
  • Carboplatin exhibited zero-order release kinetics for up to 30 days.
  • Biodegradation of microspheres occurred over time.
  • A transient, localized inflammatory response was well-tolerated.

Conclusions:

  • Intracerebral delivery of carboplatin microspheres is a safe and effective strategy for malignant glioma.
  • This local delivery approach bypasses the BBB, enhancing local drug concentration.
  • Sustained drug release and biodegradation offer potential for improved treatment outcomes and reduced systemic toxicity.